Avery Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Avery Therapeutics's estimated annual revenue is currently $2.3M per year.
- Avery Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Avery Therapeutics has 15 Employees.
- Avery Therapeutics grew their employee count by 0% last year.
Avery Therapeutics's People
Name | Title | Email/Phone |
---|
Avery Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.8M | 5 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $0.8M | 5 | -29% | N/A | N/A |
#4 | $5.3M | 34 | 0% | N/A | N/A |
#5 | $2.5M | 16 | -20% | N/A | N/A |
#6 | $1.1M | 7 | 0% | N/A | N/A |
#7 | $0.9M | 6 | 0% | N/A | N/A |
#8 | $2.2M | 29 | 21% | $58.2M | N/A |
#9 | $171.9M | 1109 | -3% | N/A | N/A |
#10 | $0.9M | 6 | 0% | N/A | N/A |
What Is Avery Therapeutics?
Avery Therapeutics’ mission is to advance tissue-engineered therapeutics to treat diseases and injuries to human muscle. Avery’s first product, MyCardia™ is a tissue engineered graft for treatment of chronic heart failure. Chronic heart failure is a critical need worldwide with 26M people diagnosed and no therapies that effectively reverse the disease process or restore function to the heart long term. MyCardia™ has the potential to be the first available therapy that regenerates tissue and restores the heart to effective function for a high quality of life. MyCardia™ is a three part product comprised of a bio- absorbable scaffold seeded with fibroblasts and induced pluripotent stem cell derived cardiomyocytes. Each cell type provides a unique therapeutic element and taken together synergistically improves the heart. MyCardia™ mimics key molecular and cellular attributes of cardiac tissue and behaves like cardiac tissue. MyCardia™ beats spontaneously and synchronously and electrically couples with the heart. We have data showing that MyCardia™ improves cardiac function in pre-clinical models of heart failure and results in generation of new blood vessels and heart muscle. Of additional importance is that pre-clinical studies with MyCardia™ have shown improvements in diastolic function, which has the potential to be immensely impactful in the heart failure population since there are no existing therapies to treat diastolic dysfunction.
keywords:N/AN/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.3M | 15 | 36% | N/A |
#2 | $1.4M | 15 | 7% | N/A |
#3 | $1.3M | 15 | 0% | N/A |
#4 | $1.6M | 15 | -32% | N/A |
#5 | $1.3M | 15 | 0% | N/A |